RICHMOND, Calif. and NEW YORK, April 5, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) and CHDI Foundation, Inc. have announced a collaboration to develop a novel therapeutic for Huntington's disease (HD) based on Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. The ZFP therapeutic approach will target the huntingtin gene that causes HD, an inherited neurodegenerative disease for which there are currently no therapies available to slow disease progression.
“We’re very excited to bring Sangamo’s ZFP technology platform to Huntington’s disease,” said Ignacio Munoz-Sanjuan, Ph.D., Vice President, Biology at CHDI. “Our collaboration aims to develop ZFP transcription factors that will alter huntingtin expression, which has the potential to directly modify disease progression. Moreover, the versatility of ZFP technology makes it a powerful platform that can be deployed to impact various aspects of HD pathology and we look forward to working with Sangamo to develop multiple innovative therapeutic approaches for HD.”
"We are very pleased to be collaborating with CHDI, who bring tremendous experience and resources in HD to the development of a novel ZFP Therapeutic for this devastating disease," said Philip Gregory, D. Phil, Sangamo's vice president, research and chief scientific officer. "The causative genetic defect in HD - mutations in the huntingtin gene - provides a validated target for intervention using a ZFP-based approach. Our collaboration will initially focus on developing ZFP Therapeutics to lower the levels of the mutant huntingtin protein in mouse and human cells. This collaboration highlights the unique ability of our ZFP technology to drive potentially therapeutic outcomes at the genetic level."
"The addition of a program in HD expands our
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved